MARKET

BGNE

BGNE

BeiGene
NASDAQ

Real-time Quotes | Nasdaq Last Sale

358.34
-18.57
-4.93%
After Hours: 358.30 -0.04 -0.01% 18:32 01/26 EST
OPEN
365.00
PREV CLOSE
376.91
HIGH
368.99
LOW
355.74
VOLUME
429.25K
TURNOVER
--
52 WEEK HIGH
382.20
52 WEEK LOW
118.55
MARKET CAP
32.68B
P/E (TTM)
-16.8498
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
BRIEF-Novartis CEO Says M&A Not In Focus Now, Wants To Execute On Strategic Plan
reuters.com · 16h ago
The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 25)
Benzinga · 18h ago
BeiGene/EUSA Pharma's Sylvant application accepted by NMPA of China
Under priority review status, National Medical Products Administration ((NMPA)) of China has accepted EUSA Pharma & BeiGene's (BGNE) marketing application seeking approval for Sylvant (siltuximab for injection) for the treatment of adult
Seekingalpha · 1d ago
EUSA Pharma And BeiGene Announce Acceptance Of A Biologics License Application For SYLVANT In China
EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)))) today announced that the Biologics License Application (BLA) for SYLVANT® (siltuximab for injection) was accepted by the China National
Benzinga · 1d ago
BeiGene, EUSA Pharma's Biologics License Application for Sylvant Gets Priority Review From Chinese Regulator
MT Newswires · 1d ago
Do Institutions Own BeiGene, Ltd. (NASDAQ:BGNE) Shares?
If you want to know who really controls BeiGene, Ltd. ( NASDAQ:BGNE ), then you'll have to look at the makeup of its...
Simply Wall St. · 4d ago
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20)
Benzinga · 5d ago
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 19)
Benzinga · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BGNE. Analyze the recent business situations of BeiGene through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BGNE stock price target is 308.95 with a high estimate of 425.00 and a low estimate of 170.18.
EPS
Institutional Holdings
Institutions: 338
Institutional Holdings: 58.02M
% Owned: 63.63%
Shares Outstanding: 91.19M
TypeInstitutionsShares
Increased
111
5.74M
New
55
441.58K
Decreased
54
1.53M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.91%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Executive Director
John Oyler
President/General Manager
Xiaobin Wu
Co-Founder/Non-Executive Director
Xiaodong Wang
Other
Eric Hedrick
Other
Jane Huang
Secretary
Hing Ling Chau
Non-Executive Director
Anthony Hooper
Non-Executive Independent Director
Timothy Chen
Non-Executive Independent Director
Donald Glazer
Non-Executive Independent Director
Michael Goller
Non-Executive Independent Director
Ranjeev Krishana
Non-Executive Independent Director
Thomas Malley
Non-Executive Independent Director
Corazon Sanders
Non-Executive Independent Director
Jing-Shyh Su
Non-Executive Independent Director
Qingqing Yi
Non-Executive Independent Director
Qingqing YI
  • Dividends
  • Splits
  • Insider Activity
No Data
About BGNE
BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).

Webull offers kinds of Beigene Ltd (ADR) stock information, including NASDAQ:BGNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BGNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BGNE stock methods without spending real money on the virtual paper trading platform.